Bacil Pharma Ltd Reports 66.87% Increase in Profit for Q3 2025

Bacil Pharma Ltd has reported an increase of 66.87% in profit for the quarter ended 30th September 2025, compared to the same period last year. The company's revenue from operations stands at ₹ 100.25 crores, with a total revenue of ₹ 100.25 crores. The profit before tax is ₹ 89.36 crores, and the profit after tax is ₹ 66.87 crores. The company's earnings per share (EPS) are ₹ 1 for both basic and diluted. The balance sheet as of 30th September 2025 shows total assets of ₹ 3,040.47 crores and total liabilities of ₹ 1,158.10 crores. The cash flow statement for the year ended 30th September 2025 shows a negative cash flow from operating activities of ₹ 142.62 crores, a negative cash flow from investing activities of ₹ 85.67 crores, and a positive cash flow from financing activities of ₹ 160.74 crores.